July 21, 2022 8:04am

VERV’s 8.3 M share offering has been priced at $27.00 with a -$6.01 or -16.74% drop in pre-market;  Wednesday’s +$3.62, Tuesday’s +$5.98 and Monday’s +$2.60 following Friday’s -$0.49, Thursday’s -$0.97 and last Wednesday’s +$2.97 and the previous Tuesday’s +$1.72),

J.P. Morgan, Jefferies, Guggenheim Securities and William Blair are acting as joint book-running managers for the offering.

VERV focused on cardiovascular disease with single-course gene editing medicines has commenced an underwritten public offering of $200.0 million of shares of its common stock.

All of the shares are being offered by VERV and expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering at the public off